Research & Development

Can CAR-T Cell Therapy Effectively Reset the Immune System?
Research & Development Can CAR-T Cell Therapy Effectively Reset the Immune System?

Modern medical science is increasingly looking toward the most aggressive cancer treatments as a potential solution for the chronic, debilitating nature of systemic autoimmune diseases. A pioneering clinical breakthrough at the University Hospital Erlangen in Germany has demonstrated that Chimeric

Why Is the Hantavirus Cure Stuck in Development Limbo?
Research & Development Why Is the Hantavirus Cure Stuck in Development Limbo?

The unexpected deaths of three passengers aboard the cruise ship MV Hondius during its journey from Argentina to Cabo Verde have reignited a fierce debate over the global medical community’s inability to treat hantavirus infections effectively. This tragic event, which initially seemed like an

Can New Molecular Targets Finally Reverse Liver Fibrosis?
Research & Development Can New Molecular Targets Finally Reverse Liver Fibrosis?

The human liver possesses an extraordinary capacity to heal, yet when chronic injury triggers the relentless buildup of scar tissue, the organ often crosses a threshold where natural recovery feels like a distant impossibility. This biological hardening, known as fibrosis, silently accumulates

How Is CATALYST Transforming the Future of Cancer Care?
Research & Development How Is CATALYST Transforming the Future of Cancer Care?

The traditional pathway of medical research often resembles a one-way street where invaluable biological samples are used once and then shelved indefinitely in cold storage, regardless of the potential secrets they still hold. For decades, the oncology community operated under a model where each

Biogen Advances Alzheimer’s Drug to Phase 3 Despite Mixed Data
Research & Development Biogen Advances Alzheimer’s Drug to Phase 3 Despite Mixed Data

The landscape of Alzheimer’s treatment is currently undergoing a radical transformation as researchers move away from traditional methods to explore the genetic underpinnings of cognitive decay. For decades, the medical community remained hyper-focused on clearing amyloid-beta plaques, yet many

Can RGX-202 Overcome Safety Risks for FDA Approval?
Research & Development Can RGX-202 Overcome Safety Risks for FDA Approval?

Ivan Kairatov is a seasoned biopharma expert with an extensive background in the research and development of transformative genetic medicines. Having spent years navigating the complexities of viral vector technology and the rigorous demands of clinical trials, he offers a deep technical

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later